Ferrari teams face challenges two hours into Le Mans race

Benedetto Vigna Chief Executive Officer Ferrari N.V.
Benedetto Vigna Chief Executive Officer - Ferrari N.V.
0Comments

Two hours into the 93rd edition of the 24 Hours of Le Mans, the number 21 Vista AF Corse entry is leading among Ferrari 296 LMGT3 cars. Alessio Rovera is currently driving, having taken over from François Heriau. The car holds eleventh place overall.

The number 57 Kessel Racing car follows in thirteenth position with Takeshi Kimura now behind the wheel, succeeding Daniel Serra. Meanwhile, Thomas Flohr has taken over from Davide Rigon in the number 54 Vista AF Corse 296 LMGT3 and is closely pursuing in sixteenth place.

The number 193 Ziggo Sport Tempesta entry sits in eighteenth after a collision during Christopher Froggatt’s stint. Jonathan Hui is currently driving this vehicle. In nineteenth place is the number 150 Richard Mille AF Corse Ferrari, which lost positions due to a spin caused by being rear-ended by car number 33. This incident resulted in a 10-second pit stop penalty for car number 33. Prior to this setback, official driver Lilou Wadoux had impressively moved up to eleventh from a starting position of twenty-first on the grid.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.